Bifalgorithm post · 10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 10. Welireg Plus Lenvima for Advanced Kidney Cancer

Treatment Results

Treatment Results (10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 10. Welireg Plus Lenvima for Advanced Kidney Cancer) — "Appro…

Ideas in this flowchart

Treatment comparison after immunotherapy in clear cell kidney cancer
The cancer had grown after immunotherapy
Compared treatments
Welireg (belzutifan) plus Lenvima (lenvatinib)
Cabometyx (cabozantinib)
Progression was delayed longer with Welireg plus Lenvima
Median progression delay: 14.6 months versus 10.6 months
The difference in overall survival was not statistically significant
Approved Sept. 24

Bifalgorithm

Feed/

Treatment Results

No cover

Channel

10 Cancer Treatment Approvals From September 2026 and What They Mean for You

1 page

USR292600b83e2a

Ebook2w

"Approved: Sept. 24 | Read more\n\nFor clear cell kidney cancer that has grown after immunotherapy, Welireg (belzutifan) plus Lenvima (lenvatinib) delayed progression longer than Cabometyx (cabozantinib): a median of 14.6 vs 10.6 months. The difference in overall survival was not statistically significant."

Flowchart preview

👍

0 comments0 shares